KR101184666B1 - Composition for improving physiological activity of positive constitution - Google Patents
Composition for improving physiological activity of positive constitution Download PDFInfo
- Publication number
- KR101184666B1 KR101184666B1 KR1020100043807A KR20100043807A KR101184666B1 KR 101184666 B1 KR101184666 B1 KR 101184666B1 KR 1020100043807 A KR1020100043807 A KR 1020100043807A KR 20100043807 A KR20100043807 A KR 20100043807A KR 101184666 B1 KR101184666 B1 KR 101184666B1
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- weight
- constitution
- parts
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 127
- 230000001766 physiological effect Effects 0.000 title claims abstract description 20
- 206010020772 Hypertension Diseases 0.000 claims abstract description 36
- 208000006673 asthma Diseases 0.000 claims abstract description 31
- 239000000843 powder Substances 0.000 claims abstract description 23
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 21
- 235000003228 Lactuca sativa Nutrition 0.000 claims abstract description 16
- 235000013402 health food Nutrition 0.000 claims abstract description 16
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 14
- 244000068988 Glycine max Species 0.000 claims abstract description 14
- 230000002708 enhancing effect Effects 0.000 claims abstract description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 12
- 239000011707 mineral Substances 0.000 claims abstract description 12
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 11
- 235000009508 confectionery Nutrition 0.000 claims abstract description 11
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 10
- 244000299461 Theobroma cacao Species 0.000 claims abstract description 10
- 244000300264 Spinacia oleracea Species 0.000 claims abstract description 9
- 235000009337 Spinacia oleracea Nutrition 0.000 claims abstract description 9
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims abstract description 9
- 244000250129 Trigonella foenum graecum Species 0.000 claims abstract description 9
- 229940087559 grape seed Drugs 0.000 claims abstract description 9
- 235000020238 sunflower seed Nutrition 0.000 claims abstract description 9
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims abstract description 9
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims abstract description 8
- 235000017491 Bambusa tulda Nutrition 0.000 claims abstract description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920001661 Chitosan Polymers 0.000 claims abstract description 8
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims abstract description 8
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract description 8
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000000060 Malva neglecta Nutrition 0.000 claims abstract description 8
- 240000000982 Malva neglecta Species 0.000 claims abstract description 8
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims abstract description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 8
- 244000170916 Paeonia officinalis Species 0.000 claims abstract description 8
- 244000082204 Phyllostachys viridis Species 0.000 claims abstract description 8
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims abstract description 8
- 240000001462 Pleurotus ostreatus Species 0.000 claims abstract description 8
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims abstract description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000009470 Theobroma cacao Nutrition 0.000 claims abstract description 8
- 239000011425 bamboo Substances 0.000 claims abstract description 8
- 239000011575 calcium Substances 0.000 claims abstract description 8
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 8
- 239000011777 magnesium Substances 0.000 claims abstract description 8
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 8
- 239000011591 potassium Substances 0.000 claims abstract description 8
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 8
- 235000020234 walnut Nutrition 0.000 claims abstract description 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 7
- 241000132536 Cirsium Species 0.000 claims abstract description 7
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 7
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 7
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 7
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 7
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 7
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 7
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 7
- 240000000171 Crataegus monogyna Species 0.000 claims abstract description 7
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 7
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 7
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 7
- 241000758791 Juglandaceae Species 0.000 claims abstract description 7
- 240000008415 Lactuca sativa Species 0.000 claims abstract description 7
- 240000005561 Musa balbisiana Species 0.000 claims abstract description 7
- 241000237536 Mytilus edulis Species 0.000 claims abstract description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960002442 glucosamine Drugs 0.000 claims abstract description 7
- 235000020638 mussel Nutrition 0.000 claims abstract description 7
- 125000000962 organic group Chemical group 0.000 claims abstract description 7
- 235000015277 pork Nutrition 0.000 claims abstract description 7
- 244000061456 Solanum tuberosum Species 0.000 claims abstract description 6
- 235000002595 Solanum tuberosum Nutrition 0.000 claims abstract description 6
- 240000004922 Vigna radiata Species 0.000 claims abstract description 5
- 235000010721 Vigna radiata var radiata Nutrition 0.000 claims abstract description 5
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 claims abstract description 5
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 4
- 241000018646 Pinus brutia Species 0.000 claims abstract description 4
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 4
- 235000021419 vinegar Nutrition 0.000 claims abstract description 3
- 239000000052 vinegar Substances 0.000 claims abstract description 3
- 235000014749 Mentha crispa Nutrition 0.000 claims abstract 2
- 244000078639 Mentha spicata Species 0.000 claims abstract 2
- 206010039083 rhinitis Diseases 0.000 claims description 25
- 206010003645 Atopy Diseases 0.000 claims description 22
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 11
- 239000001359 coriandrum sativum l. oleoresin Substances 0.000 claims description 7
- 241000238557 Decapoda Species 0.000 claims description 6
- 240000005979 Hordeum vulgare Species 0.000 claims description 5
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 240000004371 Panax ginseng Species 0.000 claims description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 4
- 235000008434 ginseng Nutrition 0.000 claims description 4
- 241001331845 Equus asinus x caballus Species 0.000 claims description 3
- 240000000143 Turnera diffusa Species 0.000 claims description 3
- 235000004952 turnera diffusa Nutrition 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 235000014571 nuts Nutrition 0.000 claims description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 claims 2
- 241000335053 Beta vulgaris Species 0.000 claims 2
- 240000007124 Brassica oleracea Species 0.000 claims 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 23
- 239000004480 active ingredient Substances 0.000 abstract description 14
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 10
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 10
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 7
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 208000024711 extrinsic asthma Diseases 0.000 abstract description 5
- 240000003086 Cynanchum laeve Species 0.000 abstract description 4
- 241000282988 Capreolus Species 0.000 abstract description 2
- 244000018436 Coriandrum sativum Species 0.000 abstract description 2
- 241000238562 Farfantepenaeus aztecus Species 0.000 abstract description 2
- 235000021182 hors d'oeuvre Nutrition 0.000 abstract description 2
- 235000002787 Coriandrum sativum Nutrition 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 31
- 230000006872 improvement Effects 0.000 description 17
- 235000013305 food Nutrition 0.000 description 15
- 238000004519 manufacturing process Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- 241000208822 Lactuca Species 0.000 description 9
- 235000010755 mineral Nutrition 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 8
- 230000037406 food intake Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 235000001465 calcium Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 208000007530 Essential hypertension Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000237509 Patinopecten sp. Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 244000013123 dwarf bean Species 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000021331 green beans Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000020637 scallop Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000234295 Musa Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 241000408710 Hansa Species 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000040738 Sesamum orientale Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YXJHJCDOUFKMBG-BMZHGHOISA-M riboflavin sodium Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)[N-]C2=O YXJHJCDOUFKMBG-BMZHGHOISA-M 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000021259 spicy food Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940124594 traditional oriental medicine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
Abstract
본 발명은 양성체질(일반적으로 몸에 열이 많음으로 “열체질”이라 부르고 있으나 이하 “양성체질”로 표기함)의 생리 활성 증진용 조성물에 관한 것으로, 구체적으로, 포도씨, 호로파, 오가피열매, 고수씨, 상심자, 해바라기씨, 천연자 및 산사를 각각 5 내지 7% 중량과 클로렐라, 노루궁뎅이버섯, 느타리버섯, 차가버섯, L-아르긴, 전호, 과루, 건지황, 모려 및 흑대두 각각 1 내지 3% 중량과 백강잠, 우방진, 송자, 코코아열매, 창질경이, 작약, 아욱, 동과자, 상추분 각각 1 내지 2% 중량의 조성비와 다시마, 홍합, 청각, 톳, 무화과, 결명자, 녹두, 호두, 청미래덩굴, 글루코사민, 키토산 각각 0.8 내지 1.5% 중량과 미량의 율무, 어성초, 시금치, 돼지감자, 메밀, 엉겅퀴, 다시마, 사삼, 통초, 바나나분말, 죽순, 홍새우, 미네랄(칼륨, 마그네슘, 칼슘, 나트륨 동량 혼합물) 각각 0.4 내지 1.2% 중량의 조성비를 갖는 조성물이 아토피, 비염과 천식 및 고혈압 증후군 증세의 개선 효과가 있으므로, 본 발명의 생리 활성 증진용 조성물은 아토피, 비염과 천식 또는 고혈압의 치료용 약학적 조성물, 및 개선용 건강식품의 유효성분으로 유용하게 이용될 수 있다.The present invention relates to a composition for enhancing the physiological activity of a benign constitution (generally referred to as "thermo constitution" due to a lot of heat in the body, but referred to as "positive constitution"), specifically, grape seed, fenugreek, organo fruit , Coriander seeds, lettuce, sunflower seeds, natural and hawthorn, each 5 to 7% by weight and chlorella, roe deer mushroom, oyster mushroom, chaga, L-argin, hors d'oeuvres, fruit, dried orange, soybean and black soybean 1 To 3% by weight, baekpja, woojinjin, pine, cocoa fruit, spearmint, peony, mallow, confectionery, lettuce powder each 1 to 2% by weight, kelp, mussels, hearing, 톳, figs, glitches, mung beans, walnuts , Blue vine, glucosamine, chitosan 0.8-1.5% by weight and traces of yulmu, eochocho, spinach, pork potato, buckwheat, thistle, kelp, samsam, whole vinegar, banana powder, bamboo shoot, red shrimp, minerals (potassium, magnesium, calcium) Sodium equivalent horn Water) Since each composition having a composition ratio of 0.4 to 1.2% by weight has an effect of improving atopic dermatitis, rhinitis and asthma and hypertension syndrome, the composition for enhancing the physiological activity of the present invention is a pharmaceutical for treating atopic dermatitis, rhinitis and asthma or hypertension. The composition can be usefully used as an active ingredient of an improved health food.
Description
본 발명은 양성체질의 생리 활성 증진용 조성물에 관한 것이다.
The present invention relates to a composition for enhancing physiological activity of a benign constitution.
인간은 음식물을 섭취하고 소화흡수하여 생리대사를 일으키는 것을 기본으로 하여 생명을 유지하고 이를 통해 건강증진 및 건전한 사회생활을 지속하게 된다. 식품공학, 식품영양학 또는 의학 측면에서는 5대 영양소로 단백질, 지질, 탄수화물, 비타민 및 무기질 등이 필요하고 효소, 섬유질 등도 매우 중요하게 여겨진다. 서양의학에서는 이들 영양소가 대사경로를 경유하면서 분해 또는 합성되어 생체 내에서 다양한 생리 활성을 발현하는 메카니즘을 찾아내기 위하여 생화학, 면역학 및 유전공학을 비롯한 최신 과학이론과 기술을 적용하고 있으며, 건강한 생활을 유지하고 질병으로부터 벗어나기 위하여 무한한 연구와 노력을 거듭하고 있다. 또한 이의 결과로 얻어진 신물질의 효능을 규명하고 이를 신규 의약품으로 개발함으로써, 이를 통해 인간 수명은 점차 연장되고 삶의 질은 높아지고 있다.
Humans maintain life on the basis of ingesting food, digesting and absorbing it and causing menstrual metabolism, thereby promoting health and healthy social life. In terms of food engineering, food nutrition, or medicine, the five major nutrients are proteins, lipids, carbohydrates, vitamins and minerals, and enzymes, fiber, etc. are considered very important. Western medicine applies the latest scientific theories and technologies, including biochemistry, immunology and genetic engineering, to find mechanisms by which these nutrients are degraded or synthesized through metabolic pathways to express various biological activities in vivo. There is an infinite amount of research and effort to maintain and to escape from disease. In addition, by identifying the efficacy of the resulting new substance and developing it as a new drug, human life is gradually extended and quality of life is improved through this.
동양의 전통의학으로부터 우리 한의학은 음양오행설, 성미, 기미, 귀경, 경혈 및 경락 이론까지 꾸준히 계승하고 발전시켜 서양의 분석과학과 접목하여 오감에 의존한 진료체계를 과학화 및 시각화함으로써 한방 생리학 분야 또한 눈부신 발전과 연구성과를 이루고 있고, 이를 통해 인간의 건강한 생활과 삶의 질이 향상되고 있다. 하지만, 이처럼 의생명과학 분야의 발전이 지속되고 있음에도 불구하고, 난치병을 명쾌하게 치료하는 의료기술의 발전은 답보상태에 있다. 난치병 치료를 위한 연구에 많은 연구비가 지속적으로 투여되고 있으나 그에 따르는 실적은 미미하며 이에 대한 돌파구를 찾고자 IT 기술의 접목을 시도하고 있지만, 그 효과는 아직 미미한 실정이다.From traditional oriental medicine to oriental medicine, we continue to develop and develop Yin-Yang and five theories, temperaments, blemishes, earaches, acupuncture points, and meridian theories, and combine them with Western analytical science to scientifically and visualize the treatment system based on the five senses. It is achieving the achievement of research and improving the healthy life and quality of life. However, despite the continued development of medical life sciences, the development of medical technology to cure incurable diseases is in a stalemate state. Although a lot of research funds are being continuously invested in the treatment for intractable disease, the results are insignificant, and attempts to integrate IT technology to find a breakthrough, but the effect is still insignificant.
한편, 현대 의료기술로 치료가 어려워 난치성 질환으로 분류되는 각종 암, 당뇨, 아토피 및 본태성 고혈압 등은 치료에 대한 성과가 낮을 뿐 아니라, 병과 더불어 발생되는 합병증으로 고통받으며, 심하게는 생명이 단축되는 경우 또한 발생하고 있다. 이는 분석과학과 자연과학의 관점을 이해하지 못한 결과로 형성된 철학적 의식개념의 차이에서 과학이 발전되고 있기 때문으로, 난치성 치료와 그 치료제 개발에 한의학적인 관점을 적용하여 새로운 치료제를 개발하기 위한 노력이 필요한 시점이다.
Meanwhile, various cancers, diabetes, atopy, and essential hypertension, which are classified as refractory diseases due to difficult medical treatments, are not only low in performance, but also suffer from complications associated with illness, and severely shorten lives. The case is also occurring. This is because science is developing from the difference in philosophical concept of consciousness that is formed as a result of not understanding the viewpoint of analytical science and natural science. It's time.
체질은 본래 가지고 태어난 신체적인 특징과 정신적인 특징, 그리고 여러 가지 다른 특성을 지닌 개념으로, 이는 천성이기도 하고 후천적 요소의 영향이 더해지기도 한다. 이러한 체질에 기반을 두고 있는 체질 의학은 인체의 기와 동일한 약이나 식품을 이용하여 면역력을 높이는 사상의학의 한 분야로, 약 또는 식품을 이용하여 기는 같지만 인체와는 반대되는 성질을 가진 체질인 사람의 음양이 균형을 이루도록 돕는다.Constitution is a concept that has physical characteristics, mental characteristics, and many other characteristics that were born with it, which is both natural and acquired. Constitution medicine based on such constitution is a field of ideology that enhances immunity by using drugs or foods that are identical to the human body. Help yin and yang balance.
사상의학(四象醫學)이란, 사람의 체질을 특성에 따라 네 유형으로 나누고 그에 따라 병을 치유하는 개념의 체질의학으로, 사람의 체질을 사상(四象), 곧 태양(太陽)?태음(太陰)?소양(少陽)?소음(少陰)으로 나누고, 체질에 따라 성격이나 심리상태, 음식, 내장의 기능, 약리 등이 서로 다르기 때문에 같은 병이라도 그 체질에 따라 약을 달리 써야 그 효과를 극대화할 수 있다는 것을 기본 개념으로 한다.Sasang medicine is a constitution medicine of the concept of dividing a person's constitution into four types according to characteristics and healing the disease accordingly.太陰), Soyang (少陽), noise (少 나누) divided into the nature, psychological state, food, intestinal function, pharmacology, etc. are different depending on the constitution, so even if the same disease, depending on the constitution of the drug different effects The basic concept is to maximize.
사상의학에서 네 가지로 분류한 사람의 체질 중 태양인은, 폐가 크고 간이 작은 형으로 체격은 상체가 튼튼하고 하체가 약하며, 성질은 활달하고 적극적인 반면 조급하고 독선적이며 노여움을 잘 타는 체질이다. 태음인은 폐가 작고 간이 큰 형(型)으로, 체격은 큰 편이고 상체가 약하나 하체가 튼튼하며 성질은 꾸준하고 참을성이 있는 반면 욕심이 많은 체질이다. 또한, 소양인은 소화기 계통이 강하고 생식기 계통이 약하며 감정적이고 끈기가 부족한 체질이고, 소음인은 소화기 계통이 약하고 생식기 계통이 강하며 내성적?사색적인 체질로 특징지어진다. Among the four constitutions of ideology, the sun man is a large lung with a small liver. The physique is a strong upper body and weak lower body. The body is active and active, but it is urgent, self-righteous, and angry. Tainumin is a small lung and a large liver (type), the physique is large, the upper body is weak, but the lower body is strong, the nature is steady and patient, but greedy constitution. In addition, Soyangin is a strong digestive system, genital system is weak, emotional and persistent constitution, Soyman is characterized by a weak digestive system, strong genital system, resistant and speculative constitution.
한방생리학적 특성으로 태양인은 속열과 겉열, 소양인은 속열, 태음인은 속냉, 소음인은 속냉과 겉냉을 띠고 있어, 태양인과 소양인을 열이 많은 양성 체질로, 태음인과 소음인을 냉성 체질로 분류할 수 있다. 이러한 양성 체질의 태양인이 양성음식인 매운 음식, 적은 잎 식물이나 뿌리식품을 지속적으로 섭취할 때 열과 냉의 체내수화현상의 부조화로 열증인 아토피, 당뇨, 고혈압 및 순환기질환(신경통, 요통, 관절통)등이 유발되는 근거가 되기도 한다. 하지만, 아직까지 양성 체질과 음성 체질을 구분하여 생리 활성 증진을 통한 병증의 치료를 목적으로 한 조성물의 개발은 이루어지지 않고 있는 실정이다.
As a herbal physiological characteristic, the sunin is fast heat and outer heat, Soyangin is fast heat, Taeumin is fast cold, and Soin is fast cold and outer cold, so sunin and Soyangin can be classified as a benign physique, and Taeumin and Soinin are cold. . When the sun person of the positive constitution continuously eats spicy foods, small leaf plants or root foods that are benign foods, heat and cold discomfort in the body hydration causes atopic dermatitis, diabetes, hypertension and circulatory diseases (neuralgia, back pain, joint pain) It is also a reason for the back. However, the development of the composition for the treatment of the disease through the enhancement of physiological activity by distinguishing the positive constitution and negative constitution yet has not been made.
이에, 본 발명자들은 약용식물, 곡류, 수산물, 버섯류, 아미노산, 과일류 및 야채류 가운데 청량(淸)하고 한성(寒性)이 있는 식의약 재료를 선발 및 조합하여 양성체질인 태양인, 소양인의 아토피 피부질환, 고혈압, 비염, 순환기질환 등이 있는 사람의 체질 개선에 유용하게 쓸 수 있는 조성물을 개발하던 중, 포도씨, 호로파, 오가피열매, 고수씨, 상심자, 해바라기씨, 천연자 및 산사 각각 5 내지 7% 중량, 클로렐라, 노루궁뎅이버섯, 느타리버섯, 차가버섯, L-아르긴, 전호, 과루, 건지황, 모려 및 흑대두 각각 1 내지 3% 중량, 백강잠, 우방진, 송자, 코코아, 창질경이, 작약, 아욱, 동과자 및 상추분 각각 1 내지 2% 중량, 다시마, 홍합, 청각, 톳, 무화과, 결명자, 녹두, 호두, 청미래덩굴, 글루코사민, 키토산 각각 0.8 내지 1.5% 중량, 및 미량의 율무, 어성초, 시금치, 돼지감자, 메밀, 엉겅퀴, 다미아나, 사삼, 통초, 바나나분말, 죽순, 홍새우, 미네랄(칼륨, 마그네슘, 칼슘, 나트륨의 동량 혼합물)을 각각 0.4 내지 1.2% 중량의 조성비로 하는 조성물을 개발하고, 상기 조성물의 섭취에 의해 아토피, 비염과 기관지 천식 증후군 및 고혈압 증후군의 증상 개선 효과가 있음을 확인함으로써, 본 발명의 조성물을 양성 체질의 생리 활성 증진용 조성물로 이용하여 아토피, 비염과 기관지 천식 증후군 또는 고혈압 증후군의 예방 및 치료용 조성물, 또는 개선용 건강식품으로 유용하게 이용될 수 있음을 밝힘으로써, 본 발명을 완성하였다.
Accordingly, the present inventors selected and combined the medicinal plants, grains, aquatic products, mushrooms, amino acids, fruits and vegetables of the medicinal plant with a cold and cold, and a combination of medicinal ingredients Sun, Soyangin atopic skin of Soyangin While developing a composition that can be useful for improving the constitution of people with diseases, hypertension, rhinitis, and circulatory diseases, grape seed, fenugreek, organo fruit, cilantro, lettuce, sunflower seed, natural seed and mountain To 7% by weight, chlorella, sesame mushroom, oyster mushroom, chaga, L-argin, Jeho, fruit, dried orange, dried and black soybeans, respectively, 1 to 3% by weight, Baekjap, Woojin, Songja, cocoa, scallop, 1 to 2% by weight of peony, mallow, confectionery and lettuce, respectively, kelp, mussels, auditory, mussels, figs, glycine, mung bean, walnut, blue mule vine, glucosamine, chitosan 0.8 to 1.5% by weight, and traces , spinach, The composition of potato, buckwheat, thistle, damiana, ginseng, tobacco, banana powder, bamboo shoot, red shrimp, and minerals (equivalent mixture of potassium, magnesium, calcium, and sodium) in 0.4 to 1.2% by weight By confirming the effect of improving the symptoms of atopic, rhinitis and bronchial asthma syndrome and hypertension syndrome by ingestion of the composition, by using the composition of the present invention as a composition for enhancing the physiological activity of a positive constitution, atopic, rhinitis and bronchial asthma syndrome Or the present invention was completed by revealing that it can be usefully used as a composition for preventing and treating hypertension syndrome or a health food for improvement.
본 발명의 목적은 양성(열성)체질의 생리 활성 증진용 조성물, 및 이를 유효성분으로 함유하는 아토피, 비염과 천식 또는 고혈압 증후군 예방 및 치료용 약학적 조성물, 또는 개선용 건강식품을 제공하는 것이다.
It is an object of the present invention to provide a composition for enhancing physiological activity of a positive (thermal) constitution, and a pharmaceutical composition for preventing and treating atopic dermatitis, rhinitis and asthma or hypertension syndrome, or improving health food containing the same as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 포도씨, 호로파, 오가피열매, 고수씨, 상심자, 해바라기씨, 천연자 및 산사를 각각 5 내지 7 중량부를 함유하는 양성(열) 체질의 생리 활성 증진용 조성물을 제공한다.In order to achieve the above object, the present invention is for enhancing the physiological activity of the positive (heat) constitution containing 5 to 7 parts by weight of grape seed, fenugreek, organo fruit, coriander seed, lettuce, sunflower seed, natural seed and hawthorn, respectively. To provide a composition.
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 아토피 예방 및 치료용 약학적 조성물, 또는 개선용 건강식품을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating atopy, or an improved health food comprising the composition as an active ingredient.
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 비염 또는 기관지 천식 예방 및 치료용 약학적 조성물, 또는 개선용 건강식품을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing and treating rhinitis or bronchial asthma, or an improved health food comprising the composition as an active ingredient.
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 고혈압 예방 및 치료용 약학적 조성물, 또는 개선용 건강식품을 제공한다.
In addition, the present invention provides a pharmaceutical composition for preventing and treating hypertension, or an improved health food comprising the composition as an active ingredient.
본 발명의 조성물은 약용식물과 곡류, 버섯류, 수산물 등 청량한 종류만으로 선별하여 양성 체질에서 나타나는 질환에만 선택적으로 작용함으로써, 현대의학에서 완전한 치료 또는 개선 방안을 찾지 못한 아토피, 비염과 천식, 고혈압 등의 질환을 근본적으로 해소할 수 있는 새로운 방안을 제시할 뿐 아니라, 많은 국내외 성인병 치료와 난치병의 예방 및 치료에 유용하게 사용될 수 있다.
The composition of the present invention is selectively selected only by the types of medicinal plants and cereals, mushrooms, aquatic products, etc. and acts only on the diseases appearing in the benign constitution, so that atopic dermatitis, rhinitis and asthma, hypertension, etc. have not been found in modern medicine. In addition to suggesting new ways to fundamentally resolve the disease, it can be usefully used for the treatment of many domestic and foreign adult diseases and the prevention and treatment of intractable diseases.
이하 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명은 포도씨, 호로파, 오가피 열매, 고수씨, 상심자, 해바라기씨, 천연자 및 산사를 각각 5 내지 7 중량부 함유하는 양성(열)체질의 생리 활성 증진용 조성물을 제공한다.The present invention provides a composition for enhancing the physiological activity of a positive (thermal) constitution containing 5 to 7 parts by weight of grape seed, fenugreek, organza fruit, coriander seed, lettuce, sunflower seed, natural and hawthorn.
또한, 상기 조성물은 체질개선, 항산화 작용 및 항종양억제능력, 생리 활성 및 면역기능을 강화하기 위하여 클로렐라, 노루궁뎅이버섯, 느타리버섯, 차가버섯, L-아르긴, 전호, 과루, 건지황, 모려 및 흑대두로 이루어진 군으로부터 선택되는 어느 하나 이상을 각각 1 내지 3 중량부로 추가적으로 포함하는 것이 바람직하나, 이에 한정되지 않는다.In addition, the composition is a chlorella, locust mushroom, oyster mushroom, chaga, L-argin, Jeonho, fruit, dried Guhwang, soybean and so on to improve the constitution, antioxidant activity and anti-tumor suppression ability, physiological activity and immune function It is preferable to additionally include 1 to 3 parts by weight of any one or more selected from the group consisting of black soybeans, but is not limited thereto.
또한, 상기 조성물은 영양소를 증가시키고, 노폐물제거 및 콜레스테롤을 저하시키고 산화방지 작용을 촉진하기 위하여 백강잠, 우방자, 송자, 코코아, 창질경이, 작약, 아욱, 동과자 및 상추분으로 이루어진 군으로부터 선택되는 어느 하나 이상을 각각 1 내지 2 중량부로 추가적으로 포함하는 것이 바람직하나, 이에 한정되지 않는다.In addition, the composition is any one selected from the group consisting of baekjap, allies, pine nuts, cocoa, cutlery, peony, mallow, sweets and lettuce powder to increase nutrients, reduce waste and lower cholesterol and promote antioxidant activity It is preferable to additionally include one or more in an amount of 1 to 2 parts by weight, but is not limited thereto.
또한, 상기 조성물은 체내의 열을 사하고 혈열을 낮추어 인체의 생리 대사를 증강화시키고, 혈중 콜레스테롤 저하 효과를 위하여 무화과, 다시마, 홍합, 녹두, 호두, 청각, 톳, 결명자, 글루코사민, 키토산 및 청미래덩굴로 이루어진 군으로부터 선택되는 어느 하나 이상을 각각 0.8 내지 1.5 중량부로 추가적으로 포함하는 것이 바람직하나, 이에 한정되지 않는다.In addition, the composition uses the heat in the body and lowers the blood fever to enhance the physiological metabolism of the human body, and the blood cholesterol lowering effect for the effect of figs, kelp, mussels, green beans, walnuts, hearing, 톳, deficiency, glucosamine, chitosan and cheongmirae One or more selected from the group consisting of vines is preferably additionally included in each of 0.8 to 1.5 parts by weight, but is not limited thereto.
또한, 상기 조성물은 양성 체질에서 청열 작용을 일으키고, 무기물이 풍부한 상수작용제재로서 혈행을 개선시킬 수 있는 보강제 및 안정제의 교량역할 기능을 위하여, 율무, 어성초, 시금치, 돼지감자, 메밀, 엉겅퀴, 다미아나, 사삼, 통초, 바나나분말, 죽순, 작은 홍새우 및 미네랄(칼륨, 나트륨, 칼슘, 마그네슘의 동량 혼합물)로 이루어진 군으로부터 선택되는 어느 하나 이상을 각각 0.4 내지 1.2 중량부로 추가적으로 포함하는 것이 바람직하나, 이에 한정되지 않는다.In addition, the composition has a clear action in the positive constitution, and as a mineral-rich water-acting agent for the role of bridges of stabilizers and stabilizers that can improve blood circulation, yulmu, eoseongcho, spinach, pork potato, buckwheat, thistle, dami It is preferable to additionally include 0.4 to 1.2 parts by weight of any one or more selected from the group consisting of ana, ginseng, tobacco, banana powder, bamboo shoots, small shrimp, and minerals (equivalent mixture of potassium, sodium, calcium, and magnesium). It is not limited to this.
상기 원료의 사용량은 각 원료별로 생리활성을 효과적으로 증대시키는 함량을 확인한 다음, 한의학 분야에서 사용하는 상사법을 적용하여 원료 조합시 생리활성 효과를 극대화시킬 수 있는 조성비로 추가되는 것이 바람직하나, 이에 한정되지 않는다.The amount of the raw material is preferably added to the composition ratio to maximize the physiological activity of the raw material combination by applying a similar method used in the field of oriental medicine after confirming the content to effectively increase the physiological activity for each raw material, but is not limited thereto. Do not.
또한, 상기 조성물은 In addition, the composition is
1) 거친 자재는 미세 분말화하는 단계;1) fine powder to fine powder;
2) 씨앗류는 파쇄하여 젤화하는 단계;2) seeds are crushed and gelled;
3) 단계 1) 및 2)의 분말된 원자재를 그대로 혼합한 후 건조 및 정제하는 단계;3) mixing the powdered raw materials of steps 1) and 2) as it is, drying and purifying;
4) 고체 약용식물을 용매로 추출하는 단계; 및4) extracting the solid medicinal plant with a solvent; And
5) 단계 3) 및 4)의 분말제 및 추출물과 나머지 원료제품을 혼합하여 제형화하는 단계를 포함하는 방법으로 제조됨이 바람직하나, 이에 한정되지 않는다.5) It is preferably prepared by a method comprising the step of mixing and formulating the powders and extracts of steps 3) and 4) and the remaining raw product, but is not limited thereto.
상기 단계 2)의 파쇄는 로울러 압착을 통해 3회 이상 반복하는 것이 바람직하나, 이에 한정되지 않는다.The crushing of step 2) is preferably repeated three or more times through roller compaction, but is not limited thereto.
상기 단계 3)의 건조는 감압건조, 진공건조, 비등건조, 분무건조, 상온건조 또는 동결건조하는 것이 바람직하나 이에 한정하지 않고, 40 내지 45℃ 조건에서 건조되는 것이 더욱 바람직하나, 이에 한정되지 않는다.The drying of step 3) is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying, room temperature drying or lyophilization, but is not limited thereto, and more preferably dried at 40 to 45 ℃ conditions, but is not limited thereto. .
상기 단계 4)의 용매는 물, 알코올 또는 이의 혼합물, C1 내지 C4의 저급 알코올 또는 이들의 혼합 용매로부터 선택된 용매를 사용하는 것이 바람직하나 이에 한정되지 않는다. 상기 추출 방법은 열수 추출, 침지 추출, 환류 냉각 추출, 초음파 추출 및 냉침 추출 등의 추출 방법을 사용하는 것이 바람직하나, 이에 한정되지 않고, 열수 추출하는 것이 더욱 바람직하나, 이에 한정되지 않는다. 추출시 온도는 70 내지 160℃인 것이 바람직하나, 이에 한정되지 않고, 80 내지 150℃인 것이 더욱 바람직하나, 이에 한정되지 않는다.The solvent of step 4) is preferably a solvent selected from water, an alcohol or a mixture thereof, a lower alcohol of C 1 to C 4 or a mixed solvent thereof, but is not limited thereto. The extraction method is preferably using an extraction method such as hot water extraction, immersion extraction, reflux cooling extraction, ultrasonic extraction and cold needle extraction, but is not limited to this, more preferably, but not limited to hot water extraction. The extraction temperature is preferably 70 to 160 ° C., but is not limited thereto, and more preferably 80 to 150 ° C., but is not limited thereto.
상기 단계 5)의 제형화는 환제, 과립제, 분말제, 연질 캅셀제 또는 액상제의 형태인 것이 바람직하나, 이에 한정되지 않고, 환제, 과립제 또는 분말제의 형태인 것이 더욱 바람직하나, 이에 한정되지 않는다.
Formulation of step 5) is preferably in the form of pills, granules, powders, soft capsules or liquids, but is not limited to this, more preferably in the form of pills, granules or powders, but is not limited thereto. .
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 아토피 예방 및 치료용 약학적 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the prevention and treatment of atopy comprising the composition as an active ingredient.
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 비염 또는 기관지 천식 예방 및 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing and treating rhinitis or bronchial asthma comprising the composition as an active ingredient.
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 고혈압 예방 및 치료용 약학적 조성물을 제공한다.
The present invention also provides a pharmaceutical composition for preventing and treating hypertension comprising the composition as an active ingredient.
본 발명의 구체적인 실시예에서, 포도씨, 호로파, 오가피열매, 고수씨, 상심자, 해바라기씨, 천연자 및 산사 각각 5 내지 7% 중량, 클로렐라, 노루궁뎅이버섯, 느타리버섯, 차가버섯, L-아르긴, 전호, 과루, 건지황, 모려 및 흑대두 각각 1 내지 3% 중량, 백강잠, 우방진, 송자, 코코아열매, 창질경이, 작약, 아욱, 동과자 및 상추분 각각 1 내지 2% 중량, 다시마, 홍합, 청각, 톳, 무화과, 결명자, 녹두, 호두, 청미래덩굴, 글루코사민, 키토산 각각 0.8 내지 1.5% 중량, 및 미량의 율무, 어성초, 시금치, 돼지감자, 메밀, 엉겅퀴, 다시마, 사삼, 통초, 바나나분말, 죽순, 홍새우, 미네랄(칼륨, 마그네슘, 칼슘, 나트륨) 혼합물을 각각 0.4 내지 1.2% 중량의 조성비로 하는 조성물을 개발하고, 상기 제조된 본 발명의 조성물이 아토피 증후군의 개선 효과가 있는지 확인하기 위하여, 조성물을 섭취시킨 아토피 증후군이 있는 성인을 대상으로 섭취하는 기간에 따른 환부의 증세 완화율을 확인하였고, 그 결과, 본 발명의 조성물을 섭취한 후, 증세의 완화율이 섭취기간에 따라 매우 높게 증가함을 확인하였고, 5개월 후에는 80 ~ 90% 이상의 증세 완화율을 보였다. 이를 통해, 본 발명의 조성물이 아토피 증세의 개선 효과를 나타냄을 확인하였다. 이러한 결과는 한방 생리학적 관점으로 아토피 증후군의 발증 원인을 보았을 때, 아토피는 피부열에 의한 양성 체질로 인한 것으로 보기 때문에, 본 발명의 조성물이 아토피 증후군의 증세 완화에 효과적임을 확인함으로써, 본 발명의 조성물이 아토피 증후군의 피부 및 헐열을 내려주는 기능이 있어, 양성 체질의 생리 활성을 조절하여 아토피 환자들의 증상을 개선할 수 있는 것으로 사료된다.In a specific embodiment of the present invention, grape seed, fenugreek, organo fruit, coriander seed, lettuce, sunflower seed, natural and hawthorn, respectively, 5 to 7% by weight, chlorella, snail mushroom, oyster mushroom, chaga, L- 1 ~ 3% by weight of argin, Jeonho, fruits, dried Guhwang, dried and black soybeans, 1 ~ 2% by weight of Baekjajam, Woojinjin, Songja, cocoa fruit, scallop, peony, mallow, sweets and lettuce, respectively. , Hearing, 톳, fig, missing, green beans, walnuts, blue vines, glucosamine, chitosan 0.8-1.5% by weight, and traces of barley, vinegar, spinach, pork, buckwheat, thistle, kelp, samsam, whole herb, banana powder To develop a composition comprising a mixture of bamboo shoots, shrimp, minerals (potassium, magnesium, calcium, sodium) in a weight ratio of 0.4 to 1.2%, respectively, and to determine whether the composition of the present invention has an effect of improving atopic syndrome for, In the adult with atopic syndrome ingesting the composition, the symptom relief rate according to the period of ingestion was confirmed. As a result, after ingesting the composition of the present invention, the alleviation rate of the symptom increases significantly with the intake period. After 5 months, the rate of relief was over 80-90%. Through this, it was confirmed that the composition of the present invention shows an improvement effect of atopic symptoms. These results, when viewed from the physiological point of view of the onset of atopic syndrome, atopic dermatitis due to skin fever positive, because the composition of the present invention is effective in alleviating the symptoms of atopic syndrome, the composition of the present invention It is believed that this atopic dermatitis has a function of lowering the skin and fever, thereby improving the symptoms of atopic patients by regulating the physiological activity of benign constitutions.
또한, 본 발명의 또 다른 실시예에서, 본 발명의 조성물이 비염과 기관지 천식 증후군의 개선 효과가 있는지 확인하기 위하여, 조성물을 섭취시킨 비염 또는 기관지 천식 증후군이 있는 성인을 대상으로 섭취하는 기간에 따른 비염 및 기관지 천식 증후군 완화율을 확인하였고, 그 결과, 본 발명의 조성물을 섭취한 후, 비염 및 기관지 천식 증후군의 증세 완화율이 섭취기간에 따라 매우 높게 증가함을 확인하였고, 5개월 후에는 80 ~ 90% 이상의 증세 완화율을 보여 거의 정상 상태까지 도달함을 확인하였다. 이를 통해, 본 발명의 조성물이 비염과 기관지 천식 증후군 증세의 개선 효과를 나타냄을 확인하였다. 이러한 결과는 한방 생리학적 관점에서 볼 때, 양성 체질인 태양인에게서 발생되는 비염 및 천식은 인체 내 열기운의 순환인 수승화강의 부조화로 인해 입과 코가 자주 건조하고 한사가 오래 정체되어 열사(熱砂)로 남게 되어 열증에 의한 면역기능 저하로 인해 나타나는 것이다. 본 발명의 조성물이 비염 및 기관지 천식 증후군의 증세 완화에 효과적임을 확인함으로써, 본 발명의 조성물의 청열 작용과 면역기능 강화로 인한 항상성이 유지를 통한 대사기능의 활성화 효과를 통해, 양성 체질의 생리 활성을 조절하여 비염 및 천식을 갖는 사람들의 증상을 개선할 수 있는 것으로 사료된다.Further, in another embodiment of the present invention, in order to determine whether the composition of the present invention has an effect of improving the rhinitis and bronchial asthma syndrome, according to the period of ingestion in adults with the rhinitis or bronchial asthma syndrome ingested the composition Rhinitis and bronchial asthma syndrome remission rate was confirmed, and as a result, after taking the composition of the present invention, the remission rate of rhinitis and bronchial asthma syndrome was found to increase very high with the intake period, 80 after 5 months It was confirmed that it reached almost steady state by showing a symptom relief rate of ~ 90% or more. Through this, it was confirmed that the composition of the present invention exhibits an improvement effect of rhinitis and bronchial asthma syndrome. These results indicate that, from the point of view of oriental physiology, rhinitis and asthma caused by a solar constitution, which is a benign constitution, frequently dry mouth and nose due to incompatibility of Suseunghwagang, a circulation of hot cloud in the human body, and heat stroke due to long stagnation of Hansa. Will remain due to deterioration of immune function due to heat. By confirming that the composition of the present invention is effective in relieving the symptoms of rhinitis and bronchial asthma syndrome, through the activation effect of metabolic function through maintaining homeostasis due to the clearing action and strengthening immune function of the composition of the present invention, the physiological activity of positive constitution It is thought to be able to improve the symptoms of people with rhinitis and asthma by controlling.
또한, 본 발명의 또 다른 구체적인 실시예에서, 본 발명의 조성물이 고혈압 증후군의 개선 효과가 있는지 확인하기 위하여, 조성물을 섭취시킨 고혈압 증후군이 있는 성인을 대상으로 섭취하는 기간에 따른 고혈압 증세의 완화율을 확인한 결과, 본 발명의 조성물을 섭취한 후, 경증 고혈압, 조절제이용 고혈압, 만성 고혈압 및 본태성 고혈압 증후군의 증세에 대한 증세의 완화율이 섭취기간에 따라 매우 높게 증가함을 확인하였고, 5개월 후에는 80 ~ 90% 이상의 증세 완화율을 보여 거의 정상 상태까지 도달함을 확인하였다. 이를 통해, 본 발명의 조성물이 고혈압 증후군 증세의 개선 효과를 나타냄을 확인하였다. 이러한 결과는 본 발명의 조성물 중 씨앗류가 많이 가지고 있는 고급 불포화지방산의 섭취, 희소 미네랄 보충에 기인하여 상대적으로 HDL-콜레스테롤의 함량증가로 인한 혈중 중성지방과 콜레스테롤 함량의 감소가 이루어져 혈압이 내려가는 것으로 사료되며, 또한 버섯류 및 수산물인 톳, 청각, 다시마 등의 청열 이수작용에 의해 신장 및 방광의 기능에 도움을 주고, 혈행의 열사를 제거하기 때문인 것으로 사료된다.
In addition, in another specific embodiment of the present invention, to determine whether the composition of the present invention has an effect of improving the hypertension syndrome, the rate of alleviation of the symptoms of hypertension according to the period of ingestion in adults with hypertension syndrome ingested the composition As a result, after ingesting the composition of the present invention, it was confirmed that the rate of alleviation of the symptoms for the symptoms of mild hypertension, modulatory hypertension, chronic hypertension and essential hypertension syndrome increased with increasing period of time, 5 months. Afterwards, the rate of alleviation was over 80-90%, confirming that the disease reached almost normal condition. Through this, it was confirmed that the composition of the present invention exhibits an improvement effect of symptoms of hypertension syndrome. These results indicate that the blood pressure decreases due to the decrease in the content of triglyceride and cholesterol in the blood due to the increase of HDL-cholesterol content due to the intake of higher unsaturated fatty acids and rare mineral supplementation of the seeds of the present invention. In addition, mushrooms and aquatic products (톳, hearing, kelp, etc.) by the dehydration action of the kidney and bladder to help the function of the bladder, and is believed to be due to the removal of heat circulation of blood circulation.
상기 본 발명에 따른 조성물은, 조성물 총 중량에 대하여 상기 조성물을 0.1 내지 90 중량%로 포함하는 것이 바람직하나 이에 한정되지 않는다.The composition according to the present invention preferably comprises 0.1 to 90% by weight of the composition, based on the total weight of the composition, but is not limited thereto.
본 발명의 조성물은 약제의 제조에 통상적으로 사용하는 적절한 담체, 부형제 및 희석제를 더 포함할 수 있다.The composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of a medicament.
본 발명에 따른 조성물은, 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 본 발명의 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. The compositions according to the invention can be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories and sterile injectable solutions, respectively, according to conventional methods. have. Examples of carriers, excipients and diluents that can be included in the composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient in the composition of the present invention, for example, starch, calcium carbonate, sucrose (sucrose), lactose (lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
본 발명의 조성물은 경구로 투여할 수 있고, 투여량은 환자의 상태, 체중, 연령, 성별, 식이, 배설율, 질환의 중증도, 약물형태, 투여시간, 투여방법, 투여 경로 및 투여기간 등에 따라 그 범위가 다양하다. 1일 투여량은 본 발명의 조성물을 동결건조하였을 때의 양으로 0.0001㎎/㎏ 내지 500㎎/㎏, 바람직하게는 0.001㎎/㎏ 내지 100㎎/㎏ 이며, 필요에 따라 일일 1회 내지 수회로 나누어 투여할 수 있고, 1일 3회 5개월 이상 투여하는 것이 바람직하나, 이에 한정되지 않는다.
The composition of the present invention can be administered orally, the dosage is depending on the patient's condition, weight, age, sex, diet, excretion rate, severity of disease, drug form, time of administration, method of administration, route of administration and duration of administration, etc. The range varies. The daily dosage is 0.0001 mg / kg to 500 mg / kg, preferably 0.001 mg / kg to 100 mg / kg, when the composition of the present invention is lyophilized. It may be administered separately, it is preferable to administer three or more times five months or more, but is not limited thereto.
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 아토피 예방 및 개선용 건강식품을 제공한다.In addition, the present invention provides atopy prevention and improvement health food comprising the composition as an active ingredient.
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 비염 또는 기관지 천식 예방 및 개선용 건강식품을 제공한다.In addition, the present invention provides a food for preventing and improving rhinitis or bronchial asthma comprising the composition as an active ingredient.
또한, 본 발명은 상기 조성물을 유효성분으로 포함하는 고혈압 예방 및 개선용 건강식품을 제공한다.
In addition, the present invention provides a health food for preventing and improving hypertension comprising the composition as an active ingredient.
본 발명의 구체적인 실시예에서, 포도씨, 호로파, 오가피열매, 고수씨, 상심자, 해바라기씨, 천연자 및 산사 각각 5 내지 7% 중량, 클로렐라, 노루궁뎅이버섯, 느타리버섯, 차가버섯, L-아르긴, 전호, 과루, 건지황, 모려 및 흑대두 각각 1 내지 3% 중량, 백강잠, 우방진, 송자, 코코아열매, 창질경이, 작약, 아욱, 동과자 및 상추분 각각 1 내지 2% 중량, 다시마, 홍합, 청각, 톳, 무화과, 결명자, 녹두, 호두, 청미래덩굴, 글루코사민, 키토산 각각 0.8 내지 1.5% 중량, 및 미량의 율무, 어성초, 시금치, 돼지감자, 메밀, 엉겅퀴, 다시마, 사삼, 통초, 바나나분말, 죽순, 홍새우, 미네랄(칼륨, 마그네슘, 칼슘, 나트륨)혼합물을 각각 0.4 내지 1.2% 중량의 조성비로 하는 조성물을 개발하고, 상기 조성물의 섭취에 의해 아토피, 비염과 기관지 천식 증후군 및 고혈압 증후군의 증상 개선 효과가 있음을 확인하였다. 따라서, 본 발명의 조성물을 양성 체질의 생리 활성 증진용 조성물로 이용하여 아토피, 비염과 기관지 천식 증후군 또는 고혈압 증후군의 예방 및 개선용 건강식품으로 유용하게 사용될 수 있다.
In a specific embodiment of the present invention, grape seed, fenugreek, organo fruit, coriander seed, lettuce, sunflower seed, natural and hawthorn, respectively, 5 to 7% by weight, chlorella, snail mushroom, oyster mushroom, chaga, L- 1 ~ 3% by weight of argin, Jeonho, fruits, dried Guhwang, dried and black soybeans, 1 ~ 2% by weight of Baekjajam, Woojinjin, Songja, cocoa fruit, scallop, peony, mallow, sweets and lettuce, respectively. , Hearing, 톳, fig, missing, green beans, walnuts, blue vines, glucosamine, chitosan 0.8 to 1.5% by weight, and traces of yulmu, eoseongcho, spinach, pork potato, buckwheat, thistle, kelp, samsam, whole herb, banana powder , A composition of bamboo shoots, prawns, and minerals (potassium, magnesium, calcium, sodium) in a composition ratio of 0.4 to 1.2% by weight, respectively, by the ingestion of the atopic dermatitis, rhinitis and bronchial asthma syndrome and hypertension syndrome Symptom It was confirmed that there is an improvement effect. Therefore, the composition of the present invention can be usefully used as a health food for preventing and improving atopic dermatitis, rhinitis and bronchial asthma syndrome or hypertension syndrome by using the composition for enhancing the physiological activity of the positive constitution.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 드링크제, 육류, 소세지, 빵, 비스켓, 떡, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강 식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of foods to which the above-mentioned substances may be added include dairy products including drinks, meat, sausages, breads, biscuits, rice cakes, chocolates, candy, snacks, confectionery, pizza, ramen, other noodles, gums and ice cream, various soups, Beverages, alcoholic beverages, vitamin complexes, and the like, and include all healthy foods in the conventional sense.
본 발명에 따른 조성물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합양은 그의 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 건강기능식품 중의 상기 조성물의 양은 전체 식품 중량의 0.1 내지 90 중량부로 가할 수 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.The composition according to the present invention can be added as is to food or used together with other food or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to its use purpose (for prevention or improvement). In general, the amount of the composition in the dietary supplement may be added at 0.1 to 90 parts by weight of the total food weight. However, in the case of long-term intake intended for health and hygiene purposes or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 조성물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12 g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the composition as an essential ingredient in the indicated ratios, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물은 100 중량부 당 0.1 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese and chocolate), pectic acid and salts thereof, alginic acid and its Salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the composition of the present invention may contain fruit flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components may be used independently or in combination. The proportion of such additives is not so critical, but the composition of the present invention is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight.
이하, 본 발명을 실시예, 실험예 및 제조예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples and Preparation Examples.
단, 하기 실시예, 실험예 및 제조예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예, 실험예 및 제조예에 한정되는 것은 아니다.
However, the following Examples, Experimental Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples, Experimental Examples, and Preparation Examples.
<< 실시예Example 1> 본 발명의 조성물 제조 1> Preparation of the composition of the present invention
본 발명에 따른 양성 체질의 생리 활성 증진용 조성물을 제조하기 위해, 하기 [표 1]에 기재된 재료들을 품질에 따라 선별 분리하고, 거친 자재들은 미세 분말화하고, 지방의 함량이 많은 씨앗류들은 로울러 압착을 반복하여 파쇄하여 미세한 젤 상태로 만들어 분말화하고, 고체의 약용식물들은 80 ~ 150℃의 열을 가열하여 열수 추출물을 얻은 후, 상기 분말 원자재와 열수 추출물을 하기 [표 1]의 % 중량으로 혼합하여 환으로 만들어 40 ~ 45℃ 조건에서 건조하여 환제를 만들고, 또한 분말 및 과립의 형태로 제형화하여 본 발명의 조성물을 제조하였다.
In order to prepare a composition for enhancing the physiological activity of the positive constitution according to the present invention, the materials described in the following [Table 1] are screened and separated according to the quality, the coarse materials are finely powdered, and the fat-rich seeds are compressed by roller Repeatedly crushed to make a fine gel state and powdered, the solid medicinal plants are heated to 80 ~ 150 ℃ heat to obtain a hydrothermal extract, the powder raw material and the hydrothermal extract to the% weight of the following [Table 1] Mixing to make a ring and dried at 40 ~ 45 ℃ conditions to form a pill, and also formulated in the form of powder and granules to prepare a composition of the present invention.
(% 중량)content
(% weight)
<< 실험예Experimental Example 1> 본 발명의 조성물 섭취에 의한 아토피 증후군 개선 효과 1> Improvement of atopic syndrome by ingesting the composition of the present invention
본 발명의 조성물이 아토피 증후군의 개선 효과가 있는지 확인하기 위하여, 아토피 증후군이 있는 성인 30명(전북 익산시 원광대학교 IT, BT 창업보육센타에서 모집, 20 ~ 50대 성인, 남자 15명, 여자 15명)을 대상으로 상기 <실시예 1>에서 제조된 조성물을 1일 3회, 1.5 내지 2 g을 경구로 섭취하는 방법으로 시험하였다. 5개월까지 복용 후, 섭취하는 기간에 따른 아토피 증후군 완화율을 1개월 단위로 환자가 느끼는 만족도 평가(정상 상태 100%)를 통하여 환부의 증세 완화율을 확인하였다.In order to confirm whether the composition of the present invention has an improvement effect of atopic syndrome, 30 adults with atopy syndrome (recruited from Wonkwang University IT, BT Business Incubator Center, Iksan-si, Jeonbuk, adults in their 20s to 50s, 15 males, 15 females) ) Was tested by the method of orally ingesting 1.5 to 2 g of the composition prepared in Example 1 three times a day. After taking it for up to 5 months, the rate of relief of the lesions was confirmed through a patient's satisfaction evaluation (100% of normal state).
그 결과, 하기 [표 2]와 같이, 본 발명의 조성물을 섭취한 후, 아토피 증후군의 증세에 대한 환자의 만족도로 나타낸 증세의 완화율이 섭취기간에 따라 매우 높게 증가함을 확인하였고, 5개월 후에는 80 ~ 90% 이상의 증세 완화율을 보였다. As a result, as shown in the following [Table 2], after ingesting the composition of the present invention, the rate of relief of the symptoms indicated by the patient's satisfaction with the symptoms of atopic syndrome was confirmed to increase very high with the intake period, 5 months Afterwards, the rate of relief was over 80-90%.
섭취기간Symptom of lesion
Intake period
*명현 반응 : 조성물의 적응 과정에서 일시적으로 증상이 심해지는 현상
* Predictive response: A phenomenon in which symptoms worsen temporarily during the adaptation process of a composition.
따라서, 본 발명의 조성물이 아토피 증세의 개선 효과를 나타냄을 확인하였다.
Therefore, it was confirmed that the composition of the present invention shows an improvement effect of atopic symptoms.
<< 실험예Experimental Example 2> 본 발명의 조성물 섭취에 의한 비염과 기관지 천식 증후군 개선 효과 2> improvement of rhinitis and bronchial asthma syndrome by ingesting the composition of the present invention
본 발명의 조성물이 비염과 기관지 천식 증후군의 개선 효과가 있는지 확인하기 위하여, 비염 또는 기관지 천식 증후군이 있는 성인 30명(전북 익산시 원광대학교 IT, BT 창업보육센타에서 모집, 40 ~ 60대 성인, 남자 15명, 여자 15명)을 대상으로 상기 <실시예 1>에서 제조된 조성물을 1일 3회, 1.5 내지 2 g을 경구로 섭취하는 방법으로 시험하였다. 5개월까지 복용 후, 섭취하는 기간에 따른 비염 및 기관지 천식 증후군 완화율을 1개월 단위로 환자가 느끼는 만족도 평가(정상 상태 100%)를 통하여 증세 완화율을 확인하였다.In order to determine whether the composition of the present invention has an effect of improving rhinitis and bronchial asthma syndrome, 30 adults with rhinitis or bronchial asthma syndrome (recruited from IT, BT Business Incubator Center, Wonkwang University, Iksan-si, Jeonbuk, adult, 40-60s, male 15 women, 15 women) were tested by the method of orally ingesting the composition prepared in Example 1 three times a day, 1.5 to 2 g. After taking up to 5 months, the rate of alleviation was confirmed through the patient's satisfaction evaluation (100% of normal state) of rhinitis and bronchial asthma syndrome relief rate according to the intake period.
그 결과, 하기 [표 3]과 같이, 본 발명의 조성물을 섭취한 후, 비염 및 기관지 천식 증후군의 증세에 대한 환자의 만족도로 나타낸 증세의 완화율이 섭취기간에 따라 매우 높게 증가함을 확인하였고, 5개월 후에는 80 ~ 90% 이상의 증세 완화율을 보여 거의 정상 상태까지 도달함을 확인하였다.
As a result, after ingesting the composition of the present invention, as shown in Table 3, it was confirmed that the relief rate of the symptoms indicated by the patient's satisfaction with the symptoms of rhinitis and bronchial asthma syndrome increased with increasing intake period. After 5 months, the rate of alleviation was over 80-90%.
섭취 기간Symptom
Intake period
따라서, 본 발명의 조성물이 비염과 기관지 천식 증후군 증세의 개선 효과를 나타냄을 확인하였다.
Therefore, it was confirmed that the composition of the present invention exhibits an improvement effect of rhinitis and bronchial asthma syndrome.
<< 실험예Experimental Example 3> 본 발명의 조성물 섭취에 의한 고혈압 증후군 개선 효과 3> improvement of hypertension syndrome by ingesting the composition of the present invention
본 발명의 조성물이 고혈압 증후군의 개선 효과가 있는지 확인하기 위하여, 고혈압 증후군이 있는 성인 30명(전북 익산시 원광대학교 IT, BT 창업보육센타에서 모집, 40 ~ 60대 성인, 남자 15명, 여자 15명)을 대상으로 상기 <실시예 1>에서 제조된 조성물을 1일 3회, 1.5 내지 2 g을 경구로 섭취하는 방법으로 시험하였다. 5개월까지 복용 후, 섭취하는 기간에 따른 고혈압 증세의 완화율을 1개월 단위로 환자가 느끼는 관능 평가(정상 상태 100%)를 통하여 증세 완화율을 확인하였다.In order to confirm whether the composition of the present invention has an effect of improving hypertension syndrome, 30 adults with hypertension syndrome (recruited from Wonkwang University IT, BT Business Incubator Center, Iksan-si, Jeonbuk, 40-60s adults, 15 males, 15 females) ) Was tested by the method of orally ingesting 1.5 to 2 g of the composition prepared in Example 1 three times a day. After taking up to 5 months, the rate of alleviation of hypertension according to the period of ingestion was confirmed by sensory evaluation (100% of normal state).
그 결과, 하기 [표 4]와 같이, 본 발명의 조성물을 섭취한 후, 경증 고혈압, 조절제이용 고혈압, 만성 고혈압 및 본태성 고혈압 증후군의 증세에 대한 환자의 만족도로 나타낸 증세의 완화율이 섭취기간에 따라 매우 높게 증가함을 확인하였고, 5개월 후에는 80 ~ 90% 이상의 증세 완화율을 보여 거의 정상 상태까지 도달함을 확인하였다.
As a result, as shown in the following [Table 4], after taking the composition of the present invention, the remission rate of the symptoms indicated by the patient's satisfaction with the symptoms of mild hypertension, hypertensive use with regulators, chronic hypertension and essential hypertension syndrome was ingestion period. It was confirmed that the increase was very high, and after 5 months, the rate of alleviation of the symptom was more than 80 to 90%, reaching almost normal condition.
섭취 기간Symptom
Intake period
따라서, 본 발명의 조성물이 고혈압 증후군 증세의 개선 효과를 나타냄을 확인하였다.
Therefore, it was confirmed that the composition of the present invention shows an improvement effect of the symptoms of hypertension syndrome.
하기에 본 발명의 조성물을 위한 제조예를 제시한다.
The preparation examples for the compositions of the present invention are given below.
<< 제조예Manufacturing example 1> 약학적 제제의 제조 1> Preparation of Pharmaceutical Formulations
1-1. 산제의 제조1-1. Manufacture of powder
본 발명의 조성물 2 g2 g of the composition of the present invention
유당 1 g1 g lactose
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above components were mixed and packed in airtight bags to prepare powders.
1-2. 정제의 제조1-2. Manufacture of tablets
본 발명의 조성물 100 ㎎100 mg of the composition of the present invention
옥수수전분 100 ㎎Corn starch 100 mg
유 당 100 ㎎100 mg of milk
스테아린산 마그네슘 2 ㎎2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
1-3. 캡슐제의 제조1-3. Preparation of capsules
본 발명의 조성물 100 ㎎100 mg of the composition of the present invention
옥수수전분 100 ㎎Corn starch 100 mg
유 당 100 ㎎100 mg of milk
스테아린산 마그네슘 2 ㎎2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
1-4. 환의 제조1-4. Manufacture of rings
본 발명의 조성물 1 g1 g of the composition of the present invention
유당 1.5 gLactose 1.5 g
글리세린 1 gGlycerin 1 g
자일리톨 0.5 g0.5 g of xylitol
상기의 성분을 혼합한 후, 통상의 방법에 따라 1 환 당 4 g이 되도록 제조하였다.
After mixing the above components, it was prepared to be 4 g per ring according to a conventional method.
1-5. 과립의 제조1-5. Preparation of Granules
본 발명의 조성물 150 ㎎150 mg of the composition of the present invention
대두 추출물 50 ㎎Soybean extract 50 mg
포도당 200 ㎎200 mg of glucose
전분 600 ㎎600 mg of starch
상기의 성분을 혼합한 후, 30% 에탄올 100 ㎎을 첨가하여 60℃에서 건조하여 과립을 형성한 후 포에 충진하였다.
After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, and then filled in fabric.
<< 제조예Manufacturing example 2> 건강기능 식품의 제조 2> Manufacture of dietary supplements
2-1. 음료의 제조2-1. Manufacturing of beverages
꿀 522 ㎎522 mg of honey
치옥토산아미 5 ㎎Chioctosanami 5 mg
니코틴산아미드 10 ㎎Nicotinamide 10 mg
염산리보플라빈나트륨 3 ㎎Riboflavin Sodium Hydrochloride 3 mg
염산피리독신 2 ㎎Pyridoxine hydrochloride 2 mg
이노시톨 30 ㎎Inositol 30 mg
오르트산 50 ㎎Orthoic acid 50 mg
본 발명의 조성물 0.48-1.28 ㎎0.48-1.28 mg of the composition of the present invention
물 200 ㎖200 ml of water
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 음료를 제조하였다. 통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 ℓ용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강식품 제조에 사용한다.With the above composition and content, drinks were prepared using conventional methods. After mixing the above components according to the conventional healthy beverage manufacturing method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored Used in the manufacture of the health food of the invention.
상기 조성비는 비교적 기호 음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호두에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a composition that is relatively suitable for the preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and national preferences such as demand hierarchy, demand country, and use purpose.
2-2. 츄잉껌의 제조2-2. Preparation of Chewing Gum
껌베이스 20%Gum Base 20%
설탕 76.36-76.76%Sugar 76.36-76.76%
본 발명의 조성물 0.24-0.64%0.24-0.64% of the composition of the present invention
후르츠향 1%1% of fruit flavor
물 2%Water 2%
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 츄잉껌을 제조하였다.
Chewing gum was prepared using the above-mentioned composition and content by a conventional method.
2-3. 캔디의 제조2-3. Manufacture of candy
설탕 50-60%50-60% sugar
물엿 39.26-49.66%Starch syrup 39.26-49.66%
본 발명의 조성물 0.24-0.64%0.24-0.64% of the composition of the present invention
오렌지향 0.1%Orange flavor 0.1%
상기 조성 및 함량으로 하여 통상적인 방법을 사용하여 캔디를 제조하였다.
The composition and the content of the candy were prepared using a conventional method.
2-4. 밀가루 식품의 제조2-4. Manufacture of flour food products
본 발명에 따른 조성물 0.5 내지 5 중량부를 밀가루 100 중량부에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.
0.5 to 5 parts by weight of the composition according to the present invention was added to 100 parts by weight of flour, and the mixture was used to prepare bread, cake, cookies, crackers, and noodles to prepare health promoting food.
2-5. 유제품(dairy products)의 제조2-5. Manufacture of dairy products
본 발명에 따른 조성물 5 내지 10 중량부를 우유 100 중량부에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
5 to 10 parts by weight of the composition according to the present invention was added to 100 parts by weight of milk, and the milk was used to prepare various dairy products such as butter and ice cream.
2-6. 선식의 제조2-6. Manufacture of wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입고 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted.
검은콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla were also steamed and dried in a known manner, and then roasted to prepare a powder having a particle size of 60 mesh.
상기에서 제조한 곡물류 및 종실류와 본 발명에 따른 조성물을 다음과 같은 비율로 배합하여 제조하였다.The grains and seeds prepared above and the composition according to the present invention were formulated in the following proportions.
현미 30%30% brown rice
율무 15%15% rate
보리 20%Barley 20%
들깨 7% Perilla 7%
검정콩 7% Black Bean 7%
검은깨 7%Black Sesame 7%
본 발명의 조성물 3%3% of the composition of the present invention
영지 0.5%Ganoderma 0.5%
지황 0.5%
Foxglove 0.5%
상기에서 살펴본 바와 같이, 본 발명의 조성물은 아토피, 비염과 천식 및 고혈압 증후군 증세의 개선 효과가 있고, 식품의약품안정청에 공시된 식용이 허용된 품목으로 이루어져 있으므로, 아토피, 비염과 천식 또는 고혈압의 치료용 약학적 조성물 및 개선용 건강식품의 유효성분으로 유용하게 이용될 수 있다.As described above, the composition of the present invention has an effect of improving the symptoms of atopic dermatitis, rhinitis and asthma and hypertension syndrome, and because it is composed of edible items disclosed in the Food and Drug Administration, treatment of atopy, rhinitis and asthma or hypertension It can be usefully used as an active ingredient of the pharmaceutical composition and the improved health food.
Claims (11)
Health food for enhancing the physiological activity of a positive (heat) constitution containing 5 to 7 parts by weight of grape seed, fenugreek, organo fruit, coriander seed, lettuce, sunflower seed, natural and hawthorn.
According to claim 1, Chlorella, roe beet mushroom, oyster mushroom, chaga, L-argin, Jeho, fruit, dried Guangji, soybeans and black soybeans each additionally added in an amount of 1 to 3 parts by weight Health food for enhancing the biological activity of the positive (heat) constitution, characterized in that.
The method according to claim 1, further comprising 1 to 2 parts by weight of one or more selected from the group consisting of baekpja sleep, allies, pine, cocoa, lanceolate, peony, mallow, sweets and lettuce powder F) Health food for enhancing the physiological activity of the constitution.
The method according to claim 1, wherein at least one selected from the group consisting of figs, kelp, mussels, mung beans, walnuts, hearing, wild boils, glitches, glucosamine, chitosan, and blue mule vines is additionally included in an amount of 0.8 to 1.5 parts by weight, respectively. Health food for enhancing the physiological activity of the benign (heat) constitution.
The composition according to claim 1, which is made of barley, spinach, spinach, pork potato, buckwheat, thistle, damiana, ginseng, tongcho, banana powder, bamboo shoot, shrimp, and minerals (equivalent mixture of potassium, sodium, calcium, magnesium). Positive (thermal) constitution physiological activity enhancing health food, characterized in that it further comprises at least 0.4 to 1.2 parts by weight each of at least one selected from the group.
Prevention of any one disease selected from the group consisting of atopy, rhinitis, bronchial asthma and hypertension, containing 5-7 parts by weight of grape seed, fenugreek, organo fruit, coriander seed, lettuce, sunflower seed, natural and hawthorn, and Therapeutic pharmaceutical composition.
According to claim 6, Chlorella, roe beet mushroom, oyster mushroom, chaga, L-argin, Jeho, fruit, dried Guangji, soybeans and black soybeans further comprises 1 to 3 parts by weight, respectively Pharmaceutical composition, characterized in that.
The pharmaceutical composition of claim 6, further comprising 1 to 2 parts by weight each of at least one selected from the group consisting of white sperm, allies, pine nuts, cocoa, spearmint, peony, mallow, cabbage, and lettuce. Composition.
The method according to claim 6, wherein at least one selected from the group consisting of figs, kelp, mussels, mung beans, walnuts, hearing, boiled, deficiencies, glucosamine, chitosan, and blue mule vines is further included in an amount of 0.8 to 1.5 parts by weight, respectively. Pharmaceutical compositions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100043807A KR101184666B1 (en) | 2010-05-11 | 2010-05-11 | Composition for improving physiological activity of positive constitution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100043807A KR101184666B1 (en) | 2010-05-11 | 2010-05-11 | Composition for improving physiological activity of positive constitution |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20110124442A KR20110124442A (en) | 2011-11-17 |
KR101184666B1 true KR101184666B1 (en) | 2012-09-20 |
Family
ID=45394189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100043807A KR101184666B1 (en) | 2010-05-11 | 2010-05-11 | Composition for improving physiological activity of positive constitution |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101184666B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101674307B1 (en) * | 2015-07-27 | 2016-11-09 | 고신대학교 산학협력단 | Composition comprising natural extracts for treating asthma and manufacturing method thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101284656B1 (en) * | 2010-12-02 | 2013-07-10 | 김미량 | Cosmetic Composition |
CN102641493A (en) * | 2012-04-22 | 2012-08-22 | 李承平 | Yang warming blood replenishing coldness dispelling stagnation removing medicine combination |
CN103566332A (en) * | 2012-08-09 | 2014-02-12 | 福建建东药业有限公司 | Fabrication technology of chill cold particles |
CN103566165A (en) * | 2012-08-09 | 2014-02-12 | 福建建东药业有限公司 | Process of exocarpium citri grandis tablets |
CN104757517A (en) * | 2015-03-20 | 2015-07-08 | 安徽徽王食品有限公司 | Canned mushroom and preparation method thereof |
CN107496797B (en) * | 2017-09-25 | 2020-06-26 | 韩旭 | Traditional Chinese medicine composition for treating bronchial asthma |
KR102013398B1 (en) * | 2018-01-10 | 2019-08-22 | 고려대학교 산학협력단 | Composition for preventing or treating cancer comprising codium extracts or fraction thereof, and trail protein |
-
2010
- 2010-05-11 KR KR1020100043807A patent/KR101184666B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101674307B1 (en) * | 2015-07-27 | 2016-11-09 | 고신대학교 산학협력단 | Composition comprising natural extracts for treating asthma and manufacturing method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20110124442A (en) | 2011-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101184666B1 (en) | Composition for improving physiological activity of positive constitution | |
KR101160943B1 (en) | Health functional foods compositions for the prevention and amelioration of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
CN107259571A (en) | One kind is for canteen thing and preparation method thereof | |
KR102262306B1 (en) | Composition for relieving premenstrual syndrome and menstrual pain | |
KR101419463B1 (en) | Herbal composition for prevention and treatment of hepatic disease | |
KR20140074422A (en) | Method for manufacturing functional pill product using silkworm | |
CN110122744A (en) | A kind of quinoa nutrient powder and preparation method thereof | |
KR101578070B1 (en) | Health supplementing food for enhancing hair restoration, alleviating and improving hair loss, adjusting blood sugar, alleviating and improving gastrointestinal disorders | |
KR20160141027A (en) | Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder | |
KR102112599B1 (en) | Anti-obesity composition comprising Punica granatum and Citrus junos extract as effective component | |
KR101509796B1 (en) | Composition for preventing or treating obesity comprising blueberry fermentation extract | |
CN113841884A (en) | Formula of instant meal replacement powder for improving nutrient metabolism and preparation method thereof | |
KR101671961B1 (en) | Manufacturing method of akebia quinata extract and functional food using the same | |
CN106974285B (en) | Traditional Chinese medicine composition and application thereof | |
KR20110051545A (en) | Composition for preventing or treating gout comprising mulberry fermentation extract | |
JP4669077B1 (en) | Autonomic nerve regulator containing asparagus pseudo-leaf as active ingredient | |
KR20110124444A (en) | Composition for improving physiological activity of cold constitution | |
KR20170014329A (en) | A food composition comprising extract of donkey | |
KR100827350B1 (en) | Herbal medicine composition for descending blood sugar | |
CN102370145A (en) | Automatic nerve regulating agent with asparagus leaf as effective ingredient | |
KR102539641B1 (en) | Kalguksu using native grass and method for manufacturing the same | |
KR101257909B1 (en) | Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
KR20110051541A (en) | Composition for preventing or treating gout comprising black galic extract | |
KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
KR102478971B1 (en) | Composition for bowel movement promotion or diet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20160801 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170710 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180702 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20191211 Year of fee payment: 8 |